Erlotinib

Generic Name
Erlotinib
Brand Names
Tarceva
Drug Type
Small Molecule
Chemical Formula
C22H23N3O4
CAS Number
183321-74-6
Unique Ingredient Identifier
J4T82NDH7E
Background

Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion...

Indication

Erlotinib is indicated for:

The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.

Associated Conditions
Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer
Associated Therapies
-
Clinical Trials
Related News

Epidermal Growth Factor Receptor Inhibition for Keratinopathies

First Posted Date
2024-08-09
Last Posted Date
2024-08-09
Lead Sponsor
Northwestern University
Target Recruit Count
44
Registration Number
NCT06545695
Locations
🇺🇸

Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

First Posted Date
2024-07-03
Last Posted Date
2024-11-15
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Target Recruit Count
104
Registration Number
NCT06483555
Locations
🇺🇸

University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors

Phase 1
Not yet recruiting
Conditions
Neoplasms
Interventions
Drug: Erlotinib
Drug: Lenvatinib
Drug: Axitinib
First Posted Date
2023-12-08
Last Posted Date
2024-12-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
70
Registration Number
NCT06161558
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer

First Posted Date
2023-06-15
Last Posted Date
2023-06-15
Lead Sponsor
Asan Medical Center
Target Recruit Count
32
Registration Number
NCT05904457
Locations
🇰🇷

Cha University Bundang Medical Center, Seongnam, Gyeonggi-do, Korea, Republic of

🇰🇷

Chungnam National University Hospital, Daejeon, Chungcheongnam-do, Korea, Republic of

🇰🇷

Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of

and more 7 locations

A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

First Posted Date
2023-04-28
Last Posted Date
2023-10-10
Lead Sponsor
Pfizer
Target Recruit Count
20605
Registration Number
NCT05834348
Locations
🇳🇴

Pfizer Norway, Oslo, Norway

Study of the CHK1 Inhibitor BBI-355, an EcDNA-directed Therapy (ecDTx), in Subjects with Tumors with Oncogene Amplifications

First Posted Date
2023-04-25
Last Posted Date
2024-12-20
Lead Sponsor
Boundless Bio
Target Recruit Count
150
Registration Number
NCT05827614
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

UCLA Medical Center, Los Angeles, California, United States

🇺🇸

Sarcoma Oncology, Santa Monica, California, United States

and more 12 locations

KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II

First Posted Date
2022-09-02
Last Posted Date
2024-11-12
Lead Sponsor
Seoul National University Bundang Hospital
Target Recruit Count
1000
Registration Number
NCT05525858
Locations
🇰🇷

Soonchunhyang University Hospital Bucheon, Bucheon, Korea, Republic of

🇰🇷

Chungbuk National University Hospital, Chungju, Korea, Republic of

🇰🇷

Keimyung University Dongsan Hospital, Daegu, Korea, Republic of

and more 29 locations

Brazilian Lung Immunotherapy Study

First Posted Date
2021-10-18
Last Posted Date
2023-10-11
Lead Sponsor
Hospital Israelita Albert Einstein
Target Recruit Count
154
Registration Number
NCT05081674
Locations
🇧🇷

Hospital Municipal Vila Santa Catarina, São Paulo, Brazil

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

First Posted Date
2021-07-29
Last Posted Date
2024-12-17
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
65
Registration Number
NCT04981509
Locations
🇺🇸

Emory University Hospital Midtown, Atlanta, Georgia, United States

🇺🇸

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

🇺🇸

Emory Saint Joseph's Hospital, Atlanta, Georgia, United States

and more 9 locations

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

First Posted Date
2020-10-19
Last Posted Date
2023-10-03
Lead Sponsor
Fondazione per la Medicina Personalizzata
Target Recruit Count
400
Registration Number
NCT04591431
Locations
🇮🇹

I.R.S.T. Srl Irccs, Meldola, Italy

🇮🇹

Ospedale Classificato Sacro Cuore - Don Calabria, Negrar, Italy

🇮🇹

I.R.C.C.S. Istituto Oncologico Veneto, Padova, Italy

and more 34 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy